Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MolecularHealth, a clinico-molecular informatics company, is set to introduce two next generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer and effective drug choices for patients.
Subscribe to our email newsletter
The company’s molecularly-guided treatment decision support solutions will initially be available for use in oncology.
The tools also integrate molecular data including whole genome sequences with clinical information about a patient, translating these data into evidence-based treatment strategies for marketed and clinical stage therapies.
Molecular Analysis of Side Effects (MASE) combines adverse event information with clinico-molecular knowledge about drug activity within a patient, the company claimed.
MolecularHealth CEO Friedrich von Bohlen said as the cost of producing genomic information is falling and clinical data is becoming increasingly accessible, the remaining challenge lies in the analysis and interpretation of this information.
"MolecularHealth has developed and is commercializing solutions that translate clinical and molecular data into actionable information, delivering precision medicine – safe and efficacious treatment decisions," Bohlen added.